Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04870944 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04870944 · ClinicalTrials.gov record · last posted 2026-08-25

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

StatusSuspended
PhasePhase 1/2
Started2022-01-28
View on ClinicalTrials.gov ↗
Why the trial stopped
Drug Supply Issues
from the ClinicalTrials.gov record
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.

Protocol amendment history 2 changes detected by DataLookout

2026-08-26
Recruitment suspended
2026-08-26
Recruitment suspended: Drug Supply Issues
Trial Details
NCT Number NCT04870944
Lead Sponsor Children's Oncology Group
Collaborators: Incuron LLC
Conditions Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27-Altered, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma +2 more
Enrollment 63 participants
Start Date 2022-01-28
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-25